AstraZeneca (AZN) and Daiichi Sankyo said Monday that an interim analysis of a phase III trial showed that Enhertu combined with pertuzumab significantly improved progression-free survival in a certain type of breast cancer, compared with standard of treatment.
The progression-free survival benefit was seen across all pre-specified patient subgroups treated with the combination.
Although the key secondary endpoint of overall survival was not mature at the time of the analysis, interim data showed an early trend favoring the Enhertu combination, compared with the standard of treatment, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.